Model for End-Stage Liver Disease (Combined MELD)

ورودی‌های بالینی بیمار

حداقل ۰.۱ — حداکثر ۵۰ • واحد: mg/dL

حداقل ۰.۱ — حداکثر ۱۵ • واحد: mg/dL

حداقل ۰.۸ — حداکثر ۱۰

حداقل ۱۲۰ — حداکثر ۱۶۰ • واحد: mEq/L

حداقل ۱ — حداکثر ۶ • واحد: g/dL

حداقل ۱۲ — حداکثر ۱۲۰ • واحد: years

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
meld score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Mild Disease6–9
  • Moderate Disease10–14
  • Severe Disease15–19
  • Very Severe Disease20–29
Direct Clinical Answer

The Model for End-Stage Liver Disease (Combined MELD) calculates assessing gastrointestinal disease severity, endoscopic intervention urgency, and rebleeding risk. Key inputs include meld version. Scores guide timing emergent endoscopy, initiating high-dose proton pump inhibitor infusions, or obtaining surgical consultation. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Offers multiple versions of MELD for liver transplant planning and end-stage liver disease severity assessment

Clinical Indication

The Model for End-Stage Liver Disease (Combined MELD) is indicated for bedside clinical practice to support Offers multiple versions of MELD for liver transplant planning and end-stage liver disease severity assessment. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with upper or lower gastrointestinal hemorrhage, acute pancreatitis, acute liver failure, or inflammatory bowel disease. Clinical application is indicated across Endoscopy suites, emergency GI triage, acute medical floors, and hepatology services.

Limitations & Contraindications

Initial hemoglobin values in hyperacute hemorrhage may falsely appear normal prior to complete extravascular-to-intravascular fluid equilibration.

Clinical Pearls & Action Plan

Aggressive intravascular volume resuscitation and blood product support must precede diagnostic or therapeutic endoscopy.

Formula & Variables:

Version-specific formulas: Original MELD = 3.78×ln(bilirubin) + 11.2×ln(INR) + 9.57×ln(creatinine) + 6.43; MELD-Na incorporates sodium; MELD 3.0 includes albumin, age, and sex adjustments

Input Parameters

NameTypeRequiredDescription
meld_versionstringYesMELD version to calculate
bilirubinfloatYesSerum bilirubin in mg/dL(mg/dL)
creatininefloatYesSerum creatinine in mg/dL(mg/dL)
inrfloatYesInternational Normalized Ratio (INR) for prothrombin time
sodiumfloatNoSerum sodium in mEq/L (required for MELD-Na and MELD 3.0)(mEq/L)
albuminfloatNoSerum albumin in g/dL (required for MELD 3.0)(g/dL)
ageintegerNoPatient age in years (required for MELD 3.0)(years)
sexstringNoPatient sex (required for MELD 3.0)
dialysis_twice_in_weekstringNoPatient received dialysis at least twice in the past week

Score Interpretation & Guidance

RangeStageDescription
6–9Mild DiseaseLower mortality risk
10–14Moderate DiseaseModerate mortality risk
15–19Severe DiseaseHigh mortality risk
20–29Very Severe DiseaseVery high mortality risk
30–40Critical DiseaseExtremely high mortality risk

Evidence-Based References (EBM)

  • Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 Feb;33(2):464-70. doi: 10.1053/jhep.2001.22172.DOI: 10.1053/jhep.2001.22172
  • Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003 Jan;124(1):91-6. doi: 10.1053/gast.2003.50016.DOI: 10.1053/gast.2003.50016
  • Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008 Sep 4;359(10):1018-26. doi: 10.1056/NEJMoa0801209.DOI: 10.1056/NEJMoa0801209
  • Kwong AJ, Ebel NH, Kim WR, Lake JR, Smith JM, Schladt DP, et al. OPTN/SRTR 2021 Annual Data Report: Liver. Am J Transplant. 2023 Feb;23(2 Suppl 1):S178-S263. doi: 10.1016/j.ajt.2023.02.006.DOI: 10.1016/j.ajt.2023.02.006
  • Kim WR, Mannalithara A, Heimbach JK, Kamath PS, Asrani SK, Biggins SW, et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021 Dec;161(6):1887-1895.e4. doi: 10.1053/j.gastro.2021.08.050.DOI: 10.1053/j.gastro.2021.08.050

Related calculators